GO:1990782 protein tyrosine kinase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990782 (protein tyrosine kinase binding) is a molecular function defined as binding to a protein tyrosine kinase, enabling targeting, scaffolding, or regulation of tyrosine kinase signaling.
• Protein tyrosine kinases (PTKs) are enzymes that transfer phosphate from ATP to tyrosine residues on substrate proteins, a central mechanism in signal transduction.
• Binding partners of PTKs include SH2 and SH3 domain-containing proteins, receptor subunits, and scaffolding proteins that assemble signaling complexes.
• Dysregulated PTK binding underlies many cancers, exemplified by BCR-ABL and KIT, and has driven development of targeted inhibitors like imatinib.
• Key PTKs such as SRC, SYK, and KIT are models for studying binding interactions, with SYK critical in immune receptor signaling.
• CRISPR-based knockout, knock-in, and point-mutation models are essential to dissect the causal roles of PTK-binding interfaces in disease.
Description
Protein tyrosine kinases (PTKs) are a large family of enzymes that catalyze the phosphorylation of tyrosine residues on target proteins, a fundamental post-translational modification in cellular signaling. The term GO:1990782, protein tyrosine kinase binding, describes the molecular function of selectively interacting with a PTK. This binding event is not merely passive; it often determines substrate specificity, subcellular localization, and the duration of kinase signaling. Researchers study this function to understand how signaling complexes assemble and how mutations in binding interfaces contribute to diseases such as cancer and immune disorders. The importance of PTK binding is underscored by the clinical success of inhibitors that block kinase activity or disrupt interactions, such as imatinib for BCR-ABL-positive leukemia. Thus, GO:1990782 represents a critical node in both basic signal transduction research and therapeutic development.
protein tyrosine kinase binding At A Glance
| GO ID | GO:1990782 |
|---|---|
| GO term | protein tyrosine kinase binding |
| Ontology | molecular_function |
| Synonym | tyrosine kinase binding |
| Major function | Binding to protein tyrosine kinases, facilitating signaling complex assembly and regulation |
| Related kinases | SRC, SYK, KIT, ABL1, JAK2, EGFR |
| Cellular context | Cytoplasm, plasma membrane, nucleus |
| Disease relevance | Cancer, immune disorders, developmental syndromes |
What Is GO:1990782?
According to the Gene Ontology, GO:1990782 (protein tyrosine kinase binding) is defined as the binding to a protein tyrosine kinase. This molecular function encompasses any interaction where a protein or other molecule selectively binds to a PTK, including interactions with the kinase domain, regulatory domains, or docking sites. It is a parent term for more specific binding functions and is distinct from kinase activity itself; it describes the recognition event rather than catalysis.
Why Is protein tyrosine kinase binding Important in Cell Biology?
Protein tyrosine kinase binding is central to cellular signal transduction because it dictates which proteins are recruited to activated kinases and how signals propagate. Aberrant binding interactions can lead to constitutive kinase activation, as seen in BCR-ABL, where the fusion protein's binding properties drive leukemogenesis. Understanding these interactions provides a rationale for designing inhibitors that block protein-protein interfaces, a growing area in drug discovery. Moreover, PTK binding is essential for normal physiology, including immune cell activation via SYK and stem cell factor signaling through KIT.
• PTK binding regulates signal transduction pathways controlling cell growth, differentiation, and survival.
• Mutations in PTK binding interfaces are implicated in cancers such as chronic myeloid leukemia and gastrointestinal stromal tumors.
• SYK binding to immunoreceptor tyrosine-based activation motifs (ITAMs) is critical for mast cell and B cell signaling.
• SRC family kinases rely on SH2 and SH3 domain-mediated binding for autoinhibition and activation.
• Targeting PTK binding interfaces offers a strategy to overcome resistance to ATP-competitive inhibitors.
• PTK binding is essential for angiogenesis, immune responses, and neuronal development.
• Dysregulated PTK binding contributes to inflammatory diseases and immunodeficiencies.
• Studying PTK binding informs the development of precision medicines and biomarker discovery.
What Happens During protein tyrosine kinase binding?
Kinase activation and conformational change
In simple terms: When a tyrosine kinase is switched on, it changes shape to expose binding sites.
Protein tyrosine kinases undergo activation via autophosphorylation or transphosphorylation, which induces conformational changes that create docking sites for binding partners. For example, SRC kinase activation involves displacement of the SH2 domain from the C-terminal phosphotyrosine, allowing the kinase domain to adopt an active conformation. These structural rearrangements are prerequisites for high-affinity binding to downstream effectors.
Recruitment of SH2 and PTB domain proteins
In simple terms: Proteins with specialized modules recognize phosphorylated tyrosines on the kinase.
Upon activation, specific phosphotyrosine residues on the kinase serve as docking sites for proteins containing SH2 or PTB domains. This binding is often of high affinity and specificity, enabling the assembly of signaling complexes. For instance, the binding of SYK to ITAMs on immune receptors is mediated by its tandem SH2 domains.
Scaffolding and signal amplification
In simple terms: Binding partners act as scaffolds that bring together other signaling molecules.
Many PTK-binding proteins function as scaffolds, coordinating the assembly of multi-protein complexes that amplify and diversify signals. For example, the binding of GRB2 to activated receptor tyrosine kinases links them to RAS-MAPK pathways. This scaffolding function is essential for processes like cell proliferation and differentiation.
Negative feedback and termination
In simple terms: Binding can also turn off the signal by recruiting inhibitory proteins.
PTK binding is not solely activating; it can recruit phosphatases or ubiquitin ligases that terminate signaling. For instance, CBL binding to activated receptor tyrosine kinases leads to receptor ubiquitination and degradation. This balance between activating and inhibitory binding events is crucial for normal cellular homeostasis.
Key Genes Involved in GO:1990782 protein tyrosine kinase binding
The following genes encode protein tyrosine kinases or their binding partners that are central to GO:1990782, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SRC | Non-receptor tyrosine kinase; prototype for SH2/SH3-mediated binding | Model for studying kinase regulation and cancer |
| SYK | Spleen tyrosine kinase; binds ITAMs in immune receptors | Critical for mast cell and B cell signaling |
| KIT | Receptor tyrosine kinase for stem cell factor | Implicated in gastrointestinal stromal tumors and mastocytosis |
| ABL1 | Non-receptor tyrosine kinase; fusion with BCR in CML | Target of imatinib; model for oncogenic PTK binding |
| JAK2 | Janus kinase; binds cytokine receptors | Driver of myeloproliferative neoplasms |
| EGFR | Receptor tyrosine kinase; binds growth factors | Target in lung and breast cancer |
| GRB2 | Adaptor protein with SH2 domain; binds activated PTKs | Links PTKs to RAS-MAPK pathway |
| PIK3R1 | Regulatory subunit of PI3K; binds phosphotyrosines | Mediates PTK-driven PI3K/AKT signaling |
| PLCG1 | Phospholipase C gamma 1; binds activated PTKs | Key effector in PTK signaling |
| CBL | E3 ubiquitin ligase; binds activated PTKs | Negatively regulates PTK signaling |
| PTPN11 | Protein tyrosine phosphatase; binds PTKs | Mutated in Noonan syndrome and leukemia |
| STAT5A | Signal transducer; binds PTKs via SH2 domain | Mediates cytokine and PTK signaling |
| CRK | Adaptor protein with SH2/SH3 domains | Regulates cytoskeletal dynamics downstream of PTKs |
| NCK1 | Adaptor protein; binds PTKs | Involved in actin cytoskeleton remodeling |
| VAV1 | Guanine nucleotide exchange factor; binds PTKs | Essential for lymphocyte activation |
| FGR | Src family kinase; binds immune receptors | Role in innate immunity |
| BTK | Bruton tyrosine kinase; binds PIP3 and PTKs | Target in B cell malignancies |
How Is protein tyrosine kinase binding Regulated?
Protein tyrosine kinase binding is regulated at multiple levels. Phosphorylation of tyrosine residues on the kinase creates or destroys binding sites, a reversible process controlled by kinases and phosphatases. For example, SRC activity is regulated by phosphorylation of Y527, which promotes intramolecular SH2 binding and autoinhibition. Additionally, the availability of binding partners can be modulated by their own phosphorylation, localization, or expression levels. In immune cells, SYK binding to ITAMs is tightly regulated by receptor engagement and phosphatase activity. Dysregulation of these regulatory mechanisms can lead to constitutive signaling and disease.
protein tyrosine kinase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCR-ABL1 | Chronic myeloid leukemia | Knock-in of BCR-ABL1 fusion in hematopoietic stem cells |
| KIT | Gastrointestinal stromal tumor | Point mutation of KIT (e.g., V560G) in cell lines |
| SYK | Autoimmune and allergic disorders | Knockout of SYK in mast cells or B cells |
| PTPN11 | Noonan syndrome | Knock-in of PTPN11 mutations in zebrafish or mice |
| SRC | Colorectal and breast cancer | Overexpression of constitutively active SRC in epithelial cells |
Cancer
Dysregulated protein tyrosine kinase binding is a hallmark of many cancers. The BCR-ABL fusion protein in chronic myeloid leukemia exhibits constitutive kinase activity and altered binding to adaptor proteins, driving proliferation. Similarly, mutations in KIT that affect its binding properties are found in gastrointestinal stromal tumors. Targeting these aberrant interactions with inhibitors like imatinib has revolutionized treatment.
Immune disorders
SYK-mediated binding to ITAMs is critical for immune receptor signaling, and its dysregulation contributes to autoimmune diseases and immunodeficiencies. For instance, aberrant SYK activation is implicated in rheumatoid arthritis and allergic disorders. Understanding the binding interfaces of SYK and related kinases may lead to new therapeutic strategies.
Developmental syndromes
Mutations in PTK-binding proteins such as PTPN11 cause Noonan syndrome and related developmental disorders by altering signaling through the RAS-MAPK pathway. These mutations often affect the binding of PTPN11 to PTKs, leading to hyperactive signaling. This highlights the importance of precise PTK binding in normal development.
From protein tyrosine kinase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTK binding affect signaling? | Knockout of the PTK or its binding partner via CRISPR |
| How does a specific phosphotyrosine mutation alter binding? | Point mutation of tyrosine to phenylalanine in the PTK |
| Can a disease-associated mutation be corrected? | Knock-in of wild-type sequence to rescue phenotype |
| Where does the binding occur in cells? | Tagged knock-in of the PTK with fluorescent protein |
| Does overexpression mimic oncogenic signaling? | Overexpression of constitutively active PTK |
| What are the downstream transcriptional changes? | RNA-seq after PTK knockout or mutation |
How to Study the protein tyrosine kinase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between proteins | Confirm binding of PTK to candidate partners |
| Mass spectrometry | Protein composition of complexes | Identify novel PTK-binding proteins |
| FRET/BRET | Real-time binding dynamics in cells | Study stimulus-dependent PTK binding |
| X-ray crystallography | Atomic structure of binding interface | Design inhibitors of PTK binding |
| CRISPR knockout screen | Genes required for PTK signaling | Discover modulators of PTK binding |
| RNA-seq | Transcriptional changes | Assess downstream effects of PTK binding |
| Phosphoproteomics | Global phosphorylation status | Map signaling networks downstream of PTKs |
Proteomics and interactomics
Affinity purification coupled with mass spectrometry (AP-MS) is widely used to identify proteins that bind to a specific PTK. By expressing a tagged kinase and pulling it down, researchers can map its interactome. This approach has revealed key binding partners like GRB2 and PLCG1. Quantitative proteomics can further determine dynamic changes in binding upon stimulation.
Structural biology
X-ray crystallography and cryo-electron microscopy provide atomic-level views of PTK-binding interfaces. For example, the structure of the SRC SH2 domain bound to a phosphopeptide has elucidated the basis of specificity. These methods are essential for rational drug design targeting binding interfaces.
Cell-based assays
Co-immunoprecipitation, FRET, and BRET assays are used to detect and quantify PTK binding in live cells. These techniques allow researchers to study binding dynamics in response to stimuli. Additionally, phospho-specific antibodies can monitor downstream signaling events.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes that modulate PTK binding and signaling. For instance, a screen for regulators of BCR-ABL signaling could uncover novel binding partners. Such screens are powerful for discovering therapeutic targets.
How CRISPR Can Be Used to Study GO:1990782 protein tyrosine kinase binding
Knockout
CRISPR knockout of a PTK or its binding partner is a powerful way to abolish the binding interaction and study its consequences. For example, knocking out SYK in immune cells eliminates ITAM-mediated signaling, providing insights into its role in mast cell activation. Knockout models are also used to validate drug targets.
Point Mutation
Introducing point mutations in the PTK or its binding interface can selectively disrupt binding without affecting kinase activity. For instance, mutating a specific tyrosine to phenylalanine in KIT can prevent docking of downstream effectors, revealing their contribution to oncogenesis. This approach is invaluable for dissecting signaling pathways.
Knock-in
Knock-in of disease-associated mutations or tagged versions of PTKs allows study of binding in a physiological context. For example, knocking in a BCR-ABL1 fusion gene into hematopoietic stem cells creates a model for chronic myeloid leukemia. Tagged knock-ins enable imaging of PTK localization and interactions.
Overexpression
Overexpression of a constitutively active PTK or its binding partner can mimic oncogenic signaling. This approach is used to study how elevated PTK binding drives proliferation and survival. Overexpression models are also useful for drug screening.
How EDITGENE Supports protein tyrosine kinase binding Research
Researchers studying protein tyrosine kinase binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease. CRISPR-based models provide the precision required to dissect these interactions, from complete knockout to subtle point mutations that disrupt binding without affecting kinase activity. EDITGENE offers a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for protein tyrosine kinase binding research.
Frequently Asked Questions About protein tyrosine kinase binding
What is GO:1990782 protein tyrosine kinase binding?
GO:1990782 is a Gene Ontology molecular function term defined as binding to a protein tyrosine kinase. It describes the selective interaction between a protein and a tyrosine kinase, which is crucial for signal transduction.
What genes are involved in protein tyrosine kinase binding?
Key genes include SRC, SYK, KIT, ABL1, JAK2, and EGFR, as well as adaptor proteins like GRB2 and CBL that bind to activated kinases.
How does protein tyrosine kinase binding affect cancer?
Aberrant binding can lead to constitutive kinase activation, driving cancers such as chronic myeloid leukemia (BCR-ABL) and gastrointestinal stromal tumors (KIT).
What methods are used to study protein tyrosine kinase binding?
Common methods include co-immunoprecipitation, mass spectrometry, FRET/BRET, X-ray crystallography, and CRISPR screens.
Can CRISPR be used to study protein tyrosine kinase binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of binding interfaces and their functional consequences.
What diseases are associated with protein tyrosine kinase binding?
Diseases include chronic myeloid leukemia, gastrointestinal stromal tumors, autoimmune disorders, and developmental syndromes like Noonan syndrome.
What is the role of SYK in protein tyrosine kinase binding?
SYK binds to ITAMs on immune receptors via its SH2 domains, initiating signaling cascades essential for mast cell and B cell activation.
How does imatinib relate to protein tyrosine kinase binding?
Imatinib is an inhibitor of BCR-ABL and other tyrosine kinases; it blocks kinase activity and downstream binding events, revolutionizing CML treatment.
What are SH2 domains and how do they relate to PTK binding?
SH2 domains are modular protein domains that bind to phosphorylated tyrosine residues on PTKs, mediating specific protein-protein interactions.
Why is protein tyrosine kinase binding important for drug discovery?
Understanding binding interfaces enables design of inhibitors that disrupt protein-protein interactions, offering new therapeutic strategies beyond ATP-competitive inhibitors.
Conclusion
GO:1990782 protein tyrosine kinase binding is a fundamental molecular function that governs cellular signaling by mediating the assembly of kinase complexes. Its dysregulation is implicated in cancer, immune disorders, and developmental syndromes, making it a prime target for therapeutic intervention. Continued research using CRISPR models and advanced proteomics will further elucidate the precise roles of PTK binding in health and disease.
References
- 1. Hubbard SR et al.. 2000. Protein tyrosine kinase structure and function.. Annu Rev Biochem 69:373-98 PMID: 10966463
- 2. Roskoski R Jr. 2005. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.. Biochem Biophys Res Commun 337(1):1-13 PMID: 16129412
- 3. Roskoski R Jr. 2004. Src protein-tyrosine kinase structure and regulation.. Biochem Biophys Res Commun 324(4):1155-64 PMID: 15504335
- 4. Tiwari RK et al.. 2012. Conformationally constrained peptides as protein tyrosine kinase inhibitors.. Curr Pharm Des 18(20):2852-66 PMID: 22571654
- 5. Siraganian RP et al.. 2002. Protein tyrosine kinase Syk in mast cell signaling.. Mol Immunol 38(16-18):1229-33 PMID: 12217388
- 6. Sada K et al.. 2001. Structure and function of Syk protein-tyrosine kinase.. J Biochem 130(2):177-86 PMID: 11481033
- 8. Roskoski R Jr. 2003. STI-571: an anticancer protein-tyrosine kinase inhibitor.. Biochem Biophys Res Commun 309(4):709-17 PMID: 13679030
